Camurus

Camurus EBIT Margin

The EBIT Margin (Operating Margin) of Camurus (CAMX.ST) as of Oct 10, 2026 is 39.03 %. In the previous year, EBIT Margin (Operating Margin) was 25.12 % — a change of 55.36% (higher).

EBIT Margin

39.03 %

YoY

55.36%

Last updated:

EBIT Margin (Operating Margin) of Camurus is 2025 39.03 % . EBIT Margin (Operating Margin) of Camurus was 2024 25.12 % . It decreases by 55.36% higher compared to the previous year.

For Camurus, the operating (EBIT) margin of 39.0% is up versus -18.7% a few years ago.

The Camurus EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-582.34 SEK
Jan 1, 2019
-340.91 SEK
Jan 1, 2020
-61.08 SEK
Jan 1, 2021
-18.71 SEK
Jan 1, 2022
7.52 SEK
Jan 1, 2023
31.01 SEK
Jan 1, 2024
25.12 SEK
Jan 1, 2025
39.03 SEK
The Camurus EBIT Margin history
YEAREBIT MarginYoY
39.03 %+55.36%
25.12 %-18.98%
31.01 %+312.11%
7.52 %-140.22%
-18.71 %-69.37%
-61.08 %-82.08%
-340.91 %-41.46%
-582.34 %+29.87%
-448.41 %+397.81%
-90.08 %-31.68%
-131.85 %-540.51%
29.93 %+4,548.19%
0.64 %+226.77%
0.20 %—
Access this data via the Eulerpool API

Camurus Stock analysis

What does Camurus do? Camurus AB is a Swedish biopharmaceutical company that specializes in the development of innovative medications for the treatment of serious diseases. The company was founded in 1991 by an interdisciplinary team of chemists, biologists, and drug developers and is headquartered in Lund, Sweden. Camurus AB specializes in the development of medications based on long-acting drug release technology. This technology allows medications to be administered in a very precise manner and over a longer period of time. This enables the benefits of a constant drug concentration in the blood to be utilized without requiring multiple doses per day. The core business of Camurus AB includes the development of medications for the treatment of pain, cancer, and addiction. The company works closely with clients, partners, and academic institutions to bring innovative medications to market that can have a significant impact on patients' lives. One of Camurus AB's key areas is pain therapy. The company has developed a novel technology that allows pain medications to be administered in the form of sprays and patches. This technology is based on the release of buprenorphine, a potent painkiller that previously could only be administered as repeated single doses or in the form of an implant due to its short half-life. The extended release allows for a sustained high concentration of the drug in the blood, without the need for the patient to take multiple single doses. Camurus AB is also active in oncology and has developed medications for the treatment of breast and prostate cancer that also utilize long-acting drug release. These medications help patients better tolerate the side effects of chemotherapy and improve their quality of life. Another important area for Camurus AB is addiction therapy. The company has developed a medication based on buprenorphine for the treatment of opioid dependence. This medication activates the body's own opioid receptors and reduces the cravings for further drugs. In recent years, Camurus AB has introduced several important products to the market and holds a wide portfolio of patents and protective rights. The company is committed to improving patient care and making global healthcare a better and more effective system. In conclusion, Camurus AB is an innovative biopharmaceutical company specializing in the development of medications for the treatment of pain, cancer, and addiction. The company is dedicated to improving global healthcare and works closely with clients, partners, and academic institutions to develop innovative, effective, and patient-oriented solutions. Camurus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Camurus stock

EBIT Margin (Operating Margin) of Camurus is 39.03 % in 2025.

EBIT Margin (Operating Margin) of Camurus changed from 25.12 % to 39.03 %, representing a 55.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Camurus since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Camurus with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — Camurus

All Key Metrics — Camurus